Allegra Medical Technologies Ltd (ASX: AMT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Allegra Medical Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $3.47 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 119.61 million
Earnings per share -0.025
Dividend per share N/A
Year To Date Return -35.56%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Allegra Medical Technologies Ltd (ASX: AMT)
    Latest News

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Share Market News

    Allegra (ASX:AMT) share price lifts 6% after reporting loss

    The Allegra (ASX: AMT) share price jumped up 6.45% today after the company released its half-yearly results. Here are the…

    Read more »

    Share Market News

    Why the Allegra (ASX:AMT) share price is rocketing 20% higher today

    The Allegra Orthopaedics Ltd (ASX: AMT) share price is surging today after the company announced an update on its flagship…

    Read more »

    AMT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Allegra Medical Technologies Ltd

    Allegra Orthopaedics Ltd. engages in the designing, prototyping and manufacturing of medical devices and surgical implants. It offers orthopaedic, spinal products, medical devices and consulting services. The company was founded by Gregory James Roger in September 1994 and is headquartered in Lane Cove West, Australia.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    09 Nov 2023 Peter Kazacos Expiry 82,452 $2,968
    Options expired.
    09 Nov 2023 Sean Mulhearn Expiry 82,452 $2,968
    Options expired.
    04 Sep 2023 Nicholas Hartnell Issued 12,758,316 $1,148,248
    Rights issue.
    04 Sep 2023 Peter Kazacos Issued 46,148 $4,153
    Rights issue.
    04 Sep 2023 Sean Mulhearn Issued 111,111 $9,999
    Rights issue.
    04 Sep 2023 Sean Mulhearn Transfer 333,333 $20,333
    Off-market transfer. Assuming off-market transfer of shares
    04 Sep 2023 Sean Mulhearn Issued 111,111 $9,999
    Rights issue.
    04 Sep 2023 Sean Mulhearn Transfer 333,333 $20,333
    Off-market transfer. Assuming off-market transfer of shares

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Peter Kazacos Non-Executive DirectorNon-Executive Chairman May 2006
    Mr Kazacos has over 40 years of experience in the IT industry. He founded KAZ in 1988, guided it from a small IT services company in NSW to one of Asia Pacific's IT services and business process outsourcing service providers with over 4,000 employees, as a fully owned subsidiary of Telstra. He also founded Anittel Ltd, building it into one of Australia's IT&C service providers operating outside the metropolitan areas, leading to its acquisition in 2010 by Anittel Group Limited (since renamed Axxis Technology Group Ltd.), representing a strategic milestone in the transformation and convergence of the IT&T industry. He is member of the Risk Committee.
    Mr Sean St Clair Mulhearn Non-Executive Director Nov 2015
    Mr Mulhearn has been involved in the financial markets for over 30 years with experience in Asia, Europe and the Americas. Sean has expertise in risk management. He founded Jacaranda Capital Partners, a boutique advisory and markets training business with offices in Singapore and Australia. He is Chair of Risk Committee.
    Dr Nicholas Hartnell Non-Executive Director Mar 2018
    Dr Hartnell as an orthopaedic surgeon brings to the Company orthopaedic industry experience. Since then, he has been focused on orthopaedic training and specialization and hence has many years of experience in all facets of Orthopaedic care. Nicholas set up his practice in Bowral in the Southern Highlands, NSW and has since expanded his surgical practice into the Goulburn, and Camden/Campbelltown areas. He is member of the Risk Committee.
    Ms Jenny Swain Chief Executive Officer May 2016
    -
    Ms Robyn Slaughter Company Secretary Feb 2022
    -
    Jenny Swain Chief Executive Officer
    -
    Robyn Slaughter Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Robinwood Investments Pty Ltd 38,274,948 36.64%
    Netwealth Investments Limited (Wrap Services A/C) 9,447,356 9.04%
    Welsh Superannuation Pty Limited 6,600,000 6.32%
    Marie Caroll & Dawson Caroll 5,636,285 5.40%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 4,958,074 4.75%
    The University Of Sydney 4,806,000 4.60%
    Dr Andrew William Leicester & Mrs Skye Christine Leicester (Leicester Super Fund A/C) 3,353,123 3.21%
    Dugal Diagnostics Pty Ltd (The Dugal Family A/C) 3,000,000 2.87%
    4 Holes In One Pty Ltd (Number 5 A/C) 3,000,000 2.87%
    Dr Andrew William Leicester & Mrs Skye Christine Leicester 2,272,270 2.18%
    Chew Investments Pty Ltd (Chew Investments A/C) 1,333,333 1.28%
    Mr Nicholas Hartnell 1,224,090 1.17%
    Mr Richard Ulrick & Mrs Wendy Ulrick (Ulrick Super Fund A/C) 1,038,318 0.99%
    Mr Thomas James Carroll 1,000,000 0.96%
    Mr Kenneth Campbell 1,000,000 0.96%
    Mergin Investments Pty Ltd (M & V Cross Super Fund A/C) 1,000,000 0.96%
    Destin Pty Limited 946,470 0.91%
    Misty Hills Nominees Pty Ltd 892,857 0.85%
    Mr Fenton Paul Healy (Cheeky Monkey A/C) 545,000 0.52%
    Desmond J Bokor Pty Limited (Kooringa Super Fund A/C) 510,000 0.49%

    Profile

    since

    Note